Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome

Patients with advanced cirrhosis and ascites are characterized by circulatory dysfunction with splanchnic vasodilatation and renal vasoconstriction, which often lead to ascites. The vasoconstrictor terlipressin improves renal function in hepatorenal syndrome (FIRS). The aim of this study was to evaluate ifterlipressin also improves renal function in patients with ascites without HRS. Twenty-three patients with cirrhosis participated, 15 with nonrefractory ascites were randomized to either terlipressin (N group, n = 11) or a placebo (P group, n = 4), and 8 had refractory ascites and received terlipressin (R group). The glomerular filtration rate (GFR), sodium clearance (C-Na), lithium clearance (C-Li), osmolal clearance (C-Osm), and urine sodium concentration (U-Na) were assessed before and after the injection of 2 mg of terlipressin or the placebo. GFR increased in the N group (69 +/- 19 versus 92 +/- 25 mL/min, P < 0.005) and in the R group (31 +/- 19 versus 41 +/- 31 mL/min, P < 0.05) after terlipressin. In the N group, terlipressin induced an increase in C-Na (0.89 +/- 0.21 versus 1.52 +/- 1.45 mL/min, P < 0.05), C-Li (17.3 +/- 8.9 versus 21.5 +/- 11.6 mL/min, P < 0.05), and C-Osm (2.10 +/- 0.81 versus 3.06 +/- 2.0 mL/min, P < 0.05). In the Rgroup, terlipressin induced an increase in C-Na (0.11 +/- 0.18 versus 0.35 +/- 0.40 mL/min, P < 0.05) and C-Li (5.5 +/- 4.2 versus 9.5 +/- 8.55 mL/min, P < 0.05). U-Na increased in both groups after terlipressin (P < 0.005). Plasma norepinephrine (P < 0.05) and renin (P < 0.05) decreased after terlipressm. All parameters remained unchanged after the placebo. Conclusion: The vasopressin 1 receptor agonist terlipressin improves renal function and induces natriuresis in patients with cirrhosis and ascites without HRS. Vasoconstrictors may represent a novel future treatment modality for these patients.